I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Atezolizumab plus Bevacizumab versus Sorafenib for Unresect..:
Li, Daneng
;
Toh, Han Chong
;
Merle, Philippe
...
Liver Cancer. 11 (2022) 6 - p. 558-571 , 2022
Link:
https://doi.org/10.1159/000525671
RT Journal T1
Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
UL https://suche.suub.uni-bremen.de/peid=cr-10.1159_000525671&Exemplar=1&LAN=DE A1 Li, Daneng A1 Toh, Han Chong A1 Merle, Philippe A1 Tsuchiya, Kaoru A1 Hernandez, Sairy A1 Verret, Wendy A1 Nicholas, Alan A1 Kudo, Masatoshi PB S. Karger AG YR 2022 SN 2235-1795 SN 1664-5553 JF Liver Cancer VO 11 IS 6 SP 558 OP 571 LK http://dx.doi.org/https://doi.org/10.1159/000525671 DO https://doi.org/10.1159/000525671 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)